expected todecline by 5% over the next 15 years, while decompen- sated cirrhosis cases and liver related mortality will increase 1–2% by 2030. To achieve the GHSS goals, a significant increase in total number of patients screened and linked to care is necessary. The number of individuals diagnosed annually would need to increase to 1.3 million by 2022 and the number of patients treated annually to 700,000 patients by the same year. Under this scenario, total viremic infections are forecasted to decline by 75% from 2015 to 2030; while decompensated cirrhosis, HCC, and liver related deaths will decline by 65% by the same year. 11,599,000 695,000 50,900 40,100 - 2,000,000 4,000,000 6,000,000 8,000,000 10,000,000 12,000,000 14,000,000 Viremic Infections Diagnosed Treated Cured Figure 1: AFRO Cascade of Care, 2016. Conclusion: Total viremic infections are expected to decline minimally in the African region over the next two decades. The WHO Goals can be achieved if drastic increases in the number of diagnosed and linked-to-care patients are met. Targeted screening strategies coupled with increased access to DAA therapy are needed to achieve these goals. THU-059 Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCVeliminating goals in the high HCV prevalent countries? S. Robbins 1 , L. Kondili 2 , S. Blach 1 , I. Gamkrelidze 1 , A. Zignego 3 , M. Brunetto 4 , G. Raimondo 5 , G. Taliani 6 , A. Iannone 7 , F.P. Russo 8 , T.A. Santantonio 9 , M.G. Zuin 10 , L. Chessa 11 , P. Blanc 12 , M. Puoti 13 , M. Vinci 14 , E.M. Erne 15 , M. Strazzabosco 16 , M. Massari 17 , P. Lampertico 18 , M.G. Rumi 19 , A. Federico 20 , C. Ferrari 21 , A. Ciancio 22 , G. Borgia 23 , P. Andreone 24 , N. Caporaso 25 , M. Persico 26 , D. Ieluzzi 27 , A. Gori 28 , A. Gasbarrini 29 , C. Coppola 30 , G.B. Gaeta 31 , A. Andriulli 32 , S. Montilla 33 , H. Razavi 1 , M. Melazzini 33 , S. Vella 2 , A. Craxi 34 . 1 Center for Disease Analysis, Polaris Observatory, Lafayette, United States; 2 Istituto Superiore di Sanità, Center for Global Health, Roma, Italy; 3 Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy; 4 Azienda Ospedaliero-Universitaria Pisa, Gastroenterology; 5 University Hospital of Messina, Internal Medicine, Messina, Italy; 6 Policlinico Umberto I, Infectious Disease, Roma, Italy; 7 Università degli Studi di Bari Aldo Moro, Gastroenterology, Bari, Italy; 8 University Hospital Padua, Gastroenterology, Padua, Italy; 9 Ospedali Riuniti, Infectious Disease, Foggia, Italy; 10 Ospedale San Paolo, Gastroenterolgy/Hepatology, Milano, Italy; 11 Policlinico Universitario Monserrato, Liver Unit, Monserrato, Italy; 12 Ospedale Santa Maria Annunziata, Infectious Disease, Ponte a Niccheri, Bagno a Ripoli, Italy; 13 Niguarda Cà Granda Hospital, Infectious Disease, MIlano, Italy; 14 Ospedale Niguarda, Hepatitis Center, Milano, Italy; 15 Azienda Ospedaliero-Universitaria Padova, Infectious Disease; 16 Ospedale San Gerardo, Hepatology, Monza, Italy; 17 Santa Maria Nuova, Infectious Disease, Santa Maria Nuova, Italy; 18 IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Gatroenterology/Hepatology, Milano, Italy; 19 Ospedale San Giuseppe, Gastroenterolgy/Hepatology, Milano, Italy; 20 Università della Campania “L. Vanvitelli”, Gastroenterolgy/ Hepatology; 21 Università degli Studi di Parma, Infectious Diseases and Hepatology, Parma, Italy; 22 Ospedale Molinette, Gastroenterology, Torino, Italy; 23 Università Federico II, Infectious Disease, Napoli, Italy; 24 Alma Mater Studiorum - Università di Bologna, Hepatology, Bologna, Italy; 25 Università degli Studi di Napoli FedericoII, Gastroenterology, Napoli, Italy; 26 Università degli Studi di Salerno, Internal Medicine and Hepatology, Fisciano, Italy; 27 Azienda Ospedaliero-Universitaria Verona, Gastroenterology; 28 Ospedale San Gerardo, Infectious Disease, Monza, Italy; 29 Università Cattolica del Sacro Cuore, Internal Medicine, Gastroenterology and Hepatology, Milano, Italy; 30 Ospedale Gragnano, Hepatology, Gragnano, Italy; 31 Università della Campania, Infectious Figure 2: (abstract THU-058) Liver Related Morbidityand Mortality by Scenario, 2016–2030. POSTER PRESENTATIONS S149 Journal of Hepatology 2018 vol. 68 | S105–S364